Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....
Innovent Biologics’ Altruist Biologics Partners with Longbio Pharma in RMB 500 Million Deal
Altruist Biologics, the Contract Development and Manufacturing Organization (CDMO) unit of China-based Innovent Biologics, Inc. (HKG:...
SSY Group Ltd Receives NMPA Approval for Stiripentol Dry Suspension for Dravet Syndrome
China-based SSY Group Ltd (HKG: 2005) has announced that it has received marketing approval from...
Novo Nordisk’s Turoctocog Alfa Pegol for Hemophilia A Accepted for Review by China’s CDE
The Center for Drug Evaluation (CDE) in China has indicated on its website that the...
Sisram Medical’s Alma Veil Launches in the US for Vascular Lesion Treatment
Alma Lasers, a subsidiary of Sisram Medical (HKG: 1696), has announced the commercial availability of...
AstraZeneca’s Eplontersen Gains Tacit Approval from CDE for ATTR-CM Clinical Study
The Center for Drug Evaluation (CDE) website indicates that UK pharmaceutical major AstraZeneca’s (AZ, NASDAQ:...
Kanova Biopharma Secures Over RMB 100 Million in Financing for Autoimmune and Oncology Pipeline
Kanova Biopharma, a Suzhou-based developer of antibodies focused on autoimmune diseases and oncology, has reportedly...
Boehringer Ingelheim Gets NMPA Approval for Phase II Study of BI 764532 in SCLC
Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical Products...
HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study
Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug...
Sosei Heptares Acquires Idorsia’s Korea and Japan Units in JPY 65 Billion Deal
Japan-based Sosei Group Corporation (TYO: 4565) has announced that its subsidiary, Sosei Heptares, has acquired...
InnoCare Pharma’s ICP-723 Receives NMPA Approval for Pediatric Clinical Study
Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases,...
Boehringer Ingelheim and Eli Lilly’s Jardiance Approved by EC for Chronic Kidney Disease
Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported...
Biogen’s Q2 2023 Report Reveals Struggles with Aduhelm and 1,000 Job Cuts
US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has released its financial report for the second quarter...
FDA Approves Daiichi Sankyo’s Vanflyta for FLT3-ITD Positive AML Maintenance Treatment
The US Food and Drug Administration (FDA) has granted clearance to Japan-based Daiichi Sankyo (TYO:...
Gilead Sciences Halts Development of Magrolimab for HR-MDS Following Phase III Trial Results
Gilead Sciences (NASDAQ: GILD) has decided to stop pursuing the potential first-in-class immunotherapy, magrolimab, for...
EU Commits EUR 3 Million to Strengthen Healthcare Access in Latin America and Caribbean
The European Union (EU) has announced a EUR 3 million (USD 3.3 million) funding injection...
AbbVie’s Aquipta and Novartis’s Piqray Receive Regulatory Approvals in Mexico
Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS) has granted registration approvals to two...
Oxford and Peking University Study Unveils Genetic Risk Factors in East Asian Population
Researchers from the UK’s Oxford Population Health and China’s Peking University have conducted a comprehensive...
Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam...
Pfizer Ends Partnership with Syros Pharmaceuticals for Sickle Cell Disease Program
Syros Pharmaceuticals Inc., (NASDAQ: SYRS) has disclosed in an SEC filing that Pfizer (NYSE: PFE)...